KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Lundbeck's new CEO discusses the company's road ahead in CNS research

Lundbeck CEO and president Deborah Dunsire talks to Jo Shorthouse about what drew her to the pharma company, which specializes in neurological disorders. She discusses the recent setback in the Phase III trial of AF35700, its novel antipsychotic in treatment resistant schizophrenia, and how the company is going to take the product forward. She also shares her thoughts on R&D in CNS, what lessons the industry has learned to date, and how it will move forward for better therapies.

Get the latest news as it happens.